Taysha Gene Therapies, Inc.

TSHA

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001806310

SEC filings (opens in a new tab)

In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Taysha Gene Therapies, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025 All holders in Q2 2025

13F holders of TSHA: Q2 2025 compared with Q3 2025
Measure	Q2 2025	Of which not filed for Q3 2025	Q3 2025	Change
Holders	150	3	155	+8
Shares	257.7M	43.7K	264.6M	+6.95M (+2.7%)
Value	$595.4M	$100.9K	$865.6M	+$270.3M (+45.4%)

3 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (28)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to TSHA in Q3 2025
Institution	Shares	Value	% of portfolio
Ally Bridge Group (NY) LLC	1,898,112	$6.21M	5.20%
Rice Hall James & Associates, LLC	578,118	$1.89M	0.10%
Boothbay Fund Management, LLC	415,607	$1.36M	0.04%
Dimensional Fund Advisors LP	345,163	$1.13M	0.00%
Readystate Asset Management LP	161,972	$529.6K	0.03%
Palumbo Wealth Management LLC	157,353	$514.5K	0.16%
Jain Global LLC	52,608	$172.0K	0.00%
Virtu Financial LLC	48,123	$157.0K	0.01%
Brevan Howard Capital Management LP	46,643	$152.5K	0.00%
State of Wisconsin Investment Board	42,949	$140.4K	0.00%
American Century Companies Inc	38,556	$126.1K	0.00%
Sender Co & Partners, Inc.	27,121	$88.7K	0.03%
CIBC Bancorp USA Inc.	22,643	$74.0K	0.00%
Russell Investments Group, Ltd.	18,165	$59.4K	0.00%
DRW Securities, LLC	16,389	$53.3K	0.00%
Cetera Investment Advisers	16,162	$52.9K	0.00%
R Squared Ltd	16,094	$52.6K	0.02%
Allegheny Financial Group LTD	15,000	$49.0K	0.01%
Bank of Montreal	13,668	$44.7K	0.00%
Arrowpoint Investment Partners (Singapore) Pte. Ltd.	12,200	$39.9K	0.06%
Aigen Investment Management, LP	10,367	$33.9K	0.01%
Rockefeller Capital Management L.P.	5,000	$16.4K	0.00%
FNY Investment Advisers, LLC	4,289	$14.0K	0.00%
Wexford Capital LP	3,500	$11.4K	0.00%
Group One Trading, L.P.	1,754	$5.74K	0.00%
Aster Capital Management (DIFC) Ltd	1,280	$4.19K	0.00%
Allworth Financial LP	215	$704	0.00%
Farther Finance Advisors, LLC	55	$180	0.00%

Sold out (20)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of TSHA in Q3 2025
Institution	Shares, Q2 2025	Value, Q2 2025
Suvretta Capital Management, LLC	3,217,449	$7.43M
MPM Oncology Impact Management LP	2,953,562	$6.82M
XTX Topco Ltd	320,737	$740.9K
ExodusPoint Capital Management, LP	148,357	$343.0K
Los Angeles Capital Management LLC	117,740	$272.0K
Omers Administration Corp	72,900	$168.4K
EntryPoint Capital, LLC	69,109	$159.6K
Renaissance Technologies LLC	54,900	$126.8K
Point72 Asia (Singapore) Pte. Ltd.	25,252	$58.3K
State Board of Administration of Florida Retirement System	22,700	$52.4K
May Hill Capital, LLC	16,051	$37.1K
Howard Capital Management Inc.	14,165	$32.7K
Marex Group plc	12,500	$28.9K
Ieq Capital, LLC	10,063	$23.2K
Atticus Wealth Management, LLC	7,425	$17.2K
Point72 (DIFC) Ltd	4,441	$10.3K
Raymond James Financial Inc	3,605	$8.33K
Headlands Technologies LLC	3,037	$7.01K
Rothschild Investment LLC	105	$243
National Bank of Canada	48	$110

Not filed for Q3 2025 yet (3)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding TSHA in Q2 2025 that haven't filed for Q3 2025
Institution	Shares, Q2 2025	Value, Q2 2025
CIBC World Markets Corp	20,417	$47.2K
E Fund Management Co., Ltd.	13,214	$30.5K
Bordeaux Wealth Advisors LLC	10,058	$23.2K